Literature DB >> 20624994

Diminished activity-dependent brain-derived neurotrophic factor expression underlies cortical neuron microcircuit hypoconnectivity resulting from exposure to mutant huntingtin fragments.

Luca Gambazzi1, Ozgun Gokce, Tamara Seredenina, Elena Katsyuba, Heike Runne, Henry Markram, Michele Giugliano, Ruth Luthi-Carter.   

Abstract

Although previous studies of Huntington's disease (HD) have addressed many potential mechanisms of striatal neuron dysfunction and death, it is also known, based on clinical findings, that cortical function is dramatically disrupted in HD. With respect to disease etiology, however, the specific molecular and neuronal circuit bases for the cortical effects of mutant huntingtin (htt) have remained largely unknown. In the present work, we studied the relationship between the molecular effects of mutant htt fragments in cortical cells and the corresponding behavior of cortical neuron microcircuits by using a novel cellular model of HD. We observed that a transcript-selective diminution in activity-dependent brain-derived neurotrophic factor (BDNF) expression preceded the onset of a synaptic connectivity deficit in ex vivo cortical networks, which manifested as decreased spontaneous collective burst-firing behavior measured by multielectrode array substrates. Decreased BDNF expression was determined to be a significant contributor to network-level dysfunction, as shown by the ability of exogenous BDNF to ameliorate cortical microcircuit burst firing. The molecular determinants of the dysregulation of activity-dependent BDNF expression by mutant htt seem to be distinct from previously elucidated mechanisms, because they do not involve known neuron-restrictive silencer factor/RE1-silencing transcription factor-regulated promoter sequences but instead result from dysregulation of BDNF exon IV and VI transcription. These data elucidate a novel HD-related deficit in BDNF gene regulation as a plausible mechanism of cortical neuron hypoconnectivity and cortical function deficits in HD. Moreover, the novel model paradigm established here is well suited to further mechanistic and drug screening research applications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20624994     DOI: 10.1124/jpet.110.167551

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

Review 1.  The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Authors:  Ravi Chopra; Vikram G Shakkottai
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

2.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.

Authors:  Ana María Estrada-Sánchez; George V Rebec
Journal:  Basal Ganglia       Date:  2012-07-01

3.  An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice.

Authors:  Brian Wilburn; Dobrila D Rudnicki; Jing Zhao; Tara Murphy Weitz; Yin Cheng; Xiaofeng Gu; Erin Greiner; Chang Sin Park; Nan Wang; Bryce L Sopher; Albert R La Spada; Alex Osmand; Russell L Margolis; Yi E Sun; X William Yang
Journal:  Neuron       Date:  2011-05-12       Impact factor: 17.173

4.  Overexpression of cypin alters dendrite morphology, single neuron activity, and network properties via distinct mechanisms.

Authors:  Ana R Rodríguez; Kate M O'Neill; Przemyslaw Swiatkowski; Mihir V Patel; Bonnie L Firestein
Journal:  J Neural Eng       Date:  2018-02       Impact factor: 5.379

5.  Potential drugs and methods for preventing or delaying the progression of Huntington's disease.

Authors:  Youssef Sari
Journal:  Recent Pat CNS Drug Discov       Date:  2011-05-01

Review 6.  Neuronal Ca(2+) dyshomeostasis in Huntington disease.

Authors:  Marta Giacomello; Juan C Oliveros; Jose R Naranjo; Ernesto Carafoli
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

7.  Huntingtin mediates anxiety/depression-related behaviors and hippocampal neurogenesis.

Authors:  Karim Ben M'Barek; Patrick Pla; Sophie Orvoen; Caroline Benstaali; Juliette D Godin; Alain M Gardier; Frédéric Saudou; Denis J David; Sandrine Humbert
Journal:  J Neurosci       Date:  2013-05-15       Impact factor: 6.167

8.  MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition.

Authors:  David M Taylor; Roger Moser; Etienne Régulier; Lionel Breuillaud; Meredith Dixon; Ayshe Ana Beesen; Linda Elliston; Mariana de Fatima Silva Santos; Jinho Kim; Lesley Jones; Darlene R Goldstein; Robert J Ferrante; Ruth Luthi-Carter
Journal:  J Neurosci       Date:  2013-02-06       Impact factor: 6.167

9.  Dysregulation of corticostriatal ascorbate release and glutamate uptake in transgenic models of Huntington's disease.

Authors:  George V Rebec
Journal:  Antioxid Redox Signal       Date:  2013-06-19       Impact factor: 8.401

Review 10.  Role of cerebral cortex in the neuropathology of Huntington's disease.

Authors:  Ana M Estrada-Sánchez; George V Rebec
Journal:  Front Neural Circuits       Date:  2013-02-18       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.